CML-366: Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers

Chitanava, Tamara; Lomaia, Elza; Shuvaev, Vasily; Martynkevich, Irina; Фоминых, М С; Efremova, Elizaveta; Kersilova, Anna; Poshivay, Agniia-Polina; Koryagina, Elena; Ilyina, Natalia; Дорофеева, Н. П.; Medvedeva, Nadezhda; Климович, А. А.; Shneider, Tatiana; Степанова, Светлана; Siordiya, Nadiya; Sbityakova, Eugenia; Lazorko, Natalia; Merzlikina, Olga; Polezhajkovskaya, Natalia; Zammoeva, Darina; Shnalieva, Nadezhda; Tochenaya, Elena; Zaritskey, Andrey

doi:10.1016/s2152-2650(20)30830-2

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 Majority of the studies reported 3-year EFS rates ranging from 28.6% to 76.4% with dasatinib/nilotinib. 50,58 In patients with prior hematologic resistance to TKI therapy, the 3-year EFS rate was reported as 28.6%, whereas in patients without prior hematologic resistance to TKI therapy it was 64.7%. 50 The 4-year EFS rate was only reported in a study evaluating allo-SCT (66.7%) in patients who were previously treated with imatinib or 2G TKIs.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review

Atallah,

Saini,

Maegawa

et al. 2023

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established. Objective: The objective of this study was to summarize the available evidence to compare the efficacy and safety of interventions in the treatment of CP-CML patients who had received ⩾2 prior TKIs. Design: A systematic literature review was performed. Data source and methods: A systematic literature review (SLR) of studies published until May 2021, reporting clinical outcomes in adult patients with CP-CML who had received ⩾ 2 prior TKIs was performed. Studies were identified through the database searches via Ovid platform (Embase, MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), bibliographic search of relevant reviews, and proceedings from the previous 3 years of the key conferences in the field of oncology. Results: Our search identified 38 relevant studies. Among the identified studies of the current third-line treatments, the major molecular response (MMR) rate for ponatinib was 19.0–66.7%, 23.3–25.5% for asciminib, 19.2% for omacetaxine, and 13.2% for bosutinib at 6 months. The complete cytogenetic response (CCyR) rate was 21.4–64.8% for ponatinib, 38.7–40.8% for asciminib, 18–24.2% for bosutinib, and 16.1% for omacetaxine at 6 months. Conclusion: The findings from current SLR demonstrated the lack of data for patients with CML treated with ⩾2 TKIs. TKIs such as asciminib, ponatinib, and bosutinib are valid options for those patients. Further research is needed to identify the best treatment option for patients with CML receiving later lines of therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…21,30,42 The 5-year OS rate ranged from 65% with mixed TKIs (dasatinib, nilotinib, bosutinib, and ponatinib) to 96% with bosutinib. 48,58 In the majority of studies, OS was not reached. Among the included interventions, bosutinib reported highest OS at 2 years, 47 ponatinib at 1 year, 42 and dasatinib or nilotinib at 3 years.…”

Section: Evidence On Efficacymentioning

confidence: 99%